Q3 EPS Estimates for AngioDynamics Lifted by HC Wainwright

AngioDynamics, Inc. (NASDAQ:ANGO) – HC Wainwright upped their Q3 2027 earnings per share (EPS) estimates for shares of AngioDynamics in a report issued on Monday, April 6th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier will post earnings of $0.00 per share for the quarter, up from their prior estimate of ($0.01). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics’ Q4 2027 earnings at $0.05 EPS.

Several other brokerages have also commented on ANGO. Zacks Research lowered AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Finally, Canaccord Genuity Group cut their target price on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $18.67.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $9.70 on Tuesday. AngioDynamics has a one year low of $8.36 and a one year high of $13.99. The stock’s 50-day moving average is $10.83 and its 200 day moving average is $11.54. The firm has a market cap of $399.83 million, a price-to-earnings ratio of -12.93 and a beta of 0.43.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The company had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP raised its stake in AngioDynamics by 8.3% during the 3rd quarter. Divisadero Street Capital Management LP now owns 3,678,125 shares of the medical instruments supplier’s stock worth $41,085,000 after buying an additional 282,695 shares during the period. Millennium Management LLC raised its stake in AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after buying an additional 393,682 shares during the period. Kotler Kevin acquired a new position in AngioDynamics during the 4th quarter worth approximately $21,997,000. Armistice Capital LLC raised its stake in AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after buying an additional 64,000 shares during the period. Finally, Weber Capital Management LLC ADV acquired a new position in AngioDynamics during the 4th quarter worth approximately $17,978,000. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.